You are here

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells

sandy craine's picture
Submitted by sandy craine on Mon, 10/09/2012 - 1:36pm
Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells
Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,

Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

sandy craine's picture
Submitted by sandy craine on Thu, 16/08/2012 - 4:29pm
'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the PACE trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD’s Phase 3 EPIC trial comparing ponatinib to imatinib that is now underway in newly diagnosed chronic-phase CML patients.

'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the PACE trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD’s Phase 3 EPIC trial comparing ponatinib to imatinib that is now underway in newly diagnosed chronic-phase CML patients.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

sandy craine's picture
Submitted by sandy craine on Fri, 06/07/2012 - 2:15pm
Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85. [Epub ahead of print]

Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85. [Epub ahead of print]

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

sandy craine's picture
Submitted by sandy craine on Tue, 03/07/2012 - 5:55pm
Leukemia advance online publication 15 June 2012; doi: 10.1038/leu.2012.134

Leukemia advance online publication
15 June 2012; doi: 10.1038/leu.2012.134

Imatinib Mesylate Discontinuation in Patients With CML Treated with Front-Line IM Therapy and Achieved Complete Molecular Response

sandy craine's picture
Submitted by sandy craine on Mon, 25/06/2012 - 7:13pm
Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak Division of Hematology/Oncology, Department of Internal Medicine, Republic of Korea.

Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak
Division of Hematology/Oncology, Department of Internal Medicine, Republic of Korea.

ASCO 2012:

sandy craine's picture
Submitted by sandy craine on Mon, 11/06/2012 - 3:46pm
PACE: Robust and Durable Antileukemic Responses With Ponatinib in Patients With Heavily Pretreated, Refractory CML or Ph+ ALL Posting Date: June 06, 2012 Updated analysis of PACE: single-arm phase II trial[1] Summary of Key Conclusions: www.clinicaloptions.com/Oncology/Conference>

PACE: Robust and Durable Antileukemic Responses With Ponatinib in Patients With Heavily Pretreated, Refractory CML or Ph+ ALL
Posting Date: June 06, 2012

Updated analysis of PACE: single-arm phase II trial[1]
Summary of Key Conclusions:
www.clinicaloptions.com/Oncology/Conference>

Pages